Is anti-D immunoglobulin still a frontline treatment option for immune thrombocytopenia?

Please use this identifier to cite or link to this item: http://dspace.hmtu.edu.vn/handle/DHKTYTHD_123/371

Full metadata record

DC Field	Value	Language
dc.contributor.author	Despotovic, Jenny M.	-
dc.contributor.author	Neunert, Cindy E.	-
dc.date.accessioned	2015-11-30T03:55:25Z	-
dc.date.available	2015-11-30T03:55:25Z	-
dc.date.issued	2013	-
dc.identifier.uri	http://220.231.117.85:8000/handle/DHKTYTHD_123/371	-
dc.description.abstract	A 5-year-old boy presents with platelet count of 2 109/L and clinical and laboratory evidence of immune thrombocytopenia. He has epistaxis and oral mucosal bleeding. Complete blood count reveals isolated thrombocytopenia without any decline in hemoglobin and he is Rh . You are asked if anti-D immunoglobulin is an appropriate initial therapy for this child given the 2010 Food and Drug Administration “black-box” warning.	vi
dc.language.iso	en	vi
dc.publisher	American Society of Hematology	vi
dc.title	Is anti-D immunoglobulin still a frontline treatment option for immune thrombocytopenia?	vi
dc.type	Article	vi
Appears in Collections	Huyết học = Hematology

Files in This Item:

File	Description	Size	Format
Hematology-2013-Despotovic-283-5.pdf Restricted Access		79.89 kB	Adobe PDF	Request Item